The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,951.00
Ask: 1,953.00
Change: -1.00 (-0.05%)
Spread: 2.00 (0.103%)
Open: 1,942.00
High: 1,958.00
Low: 1,938.00
Prev. Close: 1,959.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

Fri, 30th Apr 2021 17:01

(Alliance News) - Stocks in London ended higher on Friday rounding off an impressive month for domestic equities, characterised by robust earnings.

The FTSE 100 index closed up 8.33 points, or 0.1%, at 6,969.81 and ended up 0.5% for the week overall. Over the month, the flagship index rose 3.5%.

The FTSE 250 ended up 104.43 points, or 0.5%, at 22,497.37 and rose 0.7% since the start of the week and 5.0% over the month, during which the second-tier index hit fresh record-setting levels.

The AIM All-Share closed up 8.55 points, or 0.7%, at 1,282.71, gaining 1.5% over the course of the week.

The Cboe UK 100 ended up 0.1% at 694.00, the Cboe UK 250 closed up 0.5% at 20,143.90, and the Cboe Small Companies ended up 0.4% at 14,659.80.

In Paris the CAC 40 ended up 0.5%, while the DAX 30 in Frankfurt ended down 0.1%.

"After a decent start to the month the last two weeks have seen the FTSE 100 take a bit of a pause, and though we've struggled to maintain a foothold above 7,000, the index is still up for the third successive month in a row. It's also important to note that while the FTSE 100 has underperformed the FTSE 250 has made new record highs this month," said CMC Markets analyst Michael Hewson.

In the FTSE 100, AstraZeneca ended the best performer, up 4.3%, after the Anglo-Swedish drugmaker retained its full-year guidance as profit grew in the first quarter, expecting an "acceleration" in performance as the Covid-19 pandemic eases in the second half of this year.

Total revenue for the first three months of the year was up 15% year-on-year at USD7.32 billion, with Product Sales revenue rising 15% to make up the bulk of group revenue at USD7.26 billion, while Collaboration revenue rose 43% to GBP63 million.

Revenue from its beleaguered Covid-19 vaccine totalled USD275 million for the quarter. The jab's use has been restricted by age in many countries over links to rare blood clots - with this also listed as a side effect for the Johnson & Johnson Covid-19 vaccine - but regulatory agencies have stressed that the benefits outweigh the risks. Pretax profit for the quarter jumped 72% to USD1.61 billion from USD935 million a year ago.

Chief Executive Pascal Soriot said: "Given the performance in the first quarter, in line with our expectations, we reiterate our full-year guidance. We expect the impact of Covid to reduce and anticipate a performance acceleration in the second half of 2021."

Smurfit Kappa closed up 4.2% after the Irish corrugated packaging company said its earnings grew in the first quarter of 2021, shaking off cost pressures.

Smurfit Kappa said underlying revenue rose 6% to EUR2.27 billion in the first three months of the year. Earnings before interest, tax, depreciation and amortisation were 1.6% higher year-on-year at EUR386 million from EUR380 million.

Corrugated volume growth in Europe and the Americas was 7%, with the company citing its exposure to the e-commerce sector. Online shopping has surged due to Covid-19 lockdowns.

Hikma Pharmaceuticals ended up 3.2% after the generic drugmaker said the year is off to a "good start" with its Injectables, Generics and Branded divisions performing well and in line with expectations.

Hikma said its full-year outlook is unchanged and that it remains confident in its "ability to deliver consistent long-term, sustainable growth".

The Generics business has seen continued demand for Covid-19 related products, Hikma said, and a good performance from recent launches, which more than offset increased competition on certain products.

"We now expect our full-year Generics revenue to be towards the top end of our guidance range of USD770 million to USD810 million and core operating margin to be around 20%," said Hikma.

At the other end of the large-caps, Barclays ended the worst performer, down 7.0%. The bank posted a record quarterly profit figure as credit impairment charges were reduced.

Pretax profit was a "record" GBP2.40 billion for the first quarter of 2021, up sharply from GBP913 million a year ago, even as total income fell 6% to GBP5.90 billion. Credit impairment charges were cut by 97% to GBP55 million from GBP2.12 billion.

For the year ahead, Barclays said the outlook remains uncertain due to the pandemic but expects to deliver "meaningful" year-on-year improvement in [return on tangible equity] in 2021. The full-year impairment charge is expected to be "materially below" than of 2020's due to an improved economic outlook in the latter part of the first quarter - and if this persists, Barclays would expect to reduce the impairment provision level.

Generics revenue grew 3% to USD744 million with a core operating margin of 21.6%, improved from 17.2%.

Elsewhere in London, Darktrace closed at 330 pence, up 32% from its initial public offering price of 250p, on its first day of conditional trading in London on Friday.

This gives it a GBP2.7 billion market capitalisation and entree into the top tier among listed companies. Unconditional dealings begin on May 6.

The UK tech startup, founded in 2013, provides cybersecurity services to businesses using artificial intelligence.

The pound was quoted at USD1.3827 at the London equities close, falling from USD1.3950 at the close Thursday, as the domestic currency contends with allegations against the UK government, ahead of an eventful week.

This week, UK Prime Minister Boris Johnson has been forced to deny he broke the law, as a series of rows from lobbying to what the opposition Labour Party has dubbed "sleaze" threaten to inundate his government.

The Electoral Commission opened a probe into whether funding arrangements for the refurbishment of Johnson's apartment breached election legislation last year.

Meanwhile, next week's holiday shortened week contains the latest Bank of England monetary policy decision and economic updates on Thursday, which may well see the central bank begin to tighten policy by reducing the rate at which it purchases assets over the rest of the year.

In addition on Thursday, there are UK local elections and special attention needs to be paid to the Scottish elections where an SNP majority may see IndyRef2 back on the agenda, amid growing support for Scotland's independence from the UK.

The euro stood at USD1.2035 at the European equities close, down from USD1.2120 late Thursday, after data showed the eurozone economy shrank at the start of 2021.

Eurozone gross domestic product contracted 0.6% quarter-on-quarter for the first three months of 2021, following a 0.7% decline in the fourth quarter of 2020. The latest reading was slightly better than expectations, cited by FXStreet, for a 0.8% decline.

A technical recession is typically recognised as two consecutive quarters of GDP decline. The eurozone entered a technical recession after the second quarter print for 2020 showed a quarter-on-quarter slump of 12% after a 3.6% fall in the first three months of the year, but the bloc rebounded strongly in the third quarter of the year with growth of 13%.

Year-on-year, GDP fell 1.8% in the first quarter of 2021, moderating from the 4.9% decline seen in the previous quarter.

Against the yen, the dollar was trading at JPY109.26, up from JPY108.94 late Thursday.

Stocks in New York were lower at the London equities close, hit by a bout of profit-taking as a bountiful week of corporate earnings draws to a close.

The DJIA was down 0.5%, the S&P 500 index down 0.6% and the Nasdaq Composite down 0.3%.

Earnings and growth news have been "so good that more people are finding it hard to believe it can last," said Briefing.com analyst Patrick O'Hare. "That last thought is the essence of the 'peak growth' narrative that is emerging as a more forceful headwind for the bull market," he said.

Amazon.com was 1.1% higher after the e-commerce company other high-profile tech names in reporting blowout quarterly earnings in the wake of the coronavirus pandemic.

Social media company Twitter plunged 13% after announcing weaker-than-expected earnings and disappointing user growth, while cautious on its outlook.

Apple shed 0.8% after the EU formally accused the iPhone maker of unfairly squeezing out music streaming rivals through its App Store, which the Tim Cook-led firm firmly rejected.

Brent oil was quoted at USD67.32 a barrel at the equities close, down from USD68.35 at the close Thursday.

Gold was quoted at USD1,768.81 an ounce at the London equities close, flat from USD1,768.68 late Thursday.

The economic events calendar on Monday has manufacturing PMI readings from Germany, the eurozone and the US at 0855 BST, 0900 BST and 1445 BST respectively. Financial markets in the UK will be closed on Monday for the Early May bank holiday, while markets in Shanghai will be hut for Labor Day.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.